Developing differentiated therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases

NASH is expected to become the leading cause for liver transplants in the United States.

Inflammatory bowel disease is increasing in prevalence worldwide

Metacrine is building a pipeline of potential best-in-class FXR agonist therapeuties for NASH and other GI diseases

Our Company

We are a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and GI diseases.

Latest News

September 15, 2020

Metacrine Announces Pricing of Initial Public Offering

September 02, 2020

Metacrine Strengthens Leadership Team with Key Appointments

Programs

Our most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.

Developing differentiated therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases

NASH is expected to become the leading cause for liver transplants in the United States.

Inflammatory bowel disease is increasing in prevalence worldwide

Metacrine is building a pipeline of potential best-in-class FXR agonist therapeuties for NASH and other GI diseases

Our Company

Latest News

Metacrine Announces Pricing of Initial Public Offering

Metacrine Strengthens Leadership Team with Key Appointments

Metacrine Strengthens Leadership Team with Key Appointments

Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress™ 2020

Programs